RxDoctor Payments Data

Emily Rose, MD

Clinical Cardiac Electrophysiology · Muncie, INNPI 1699793117

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biosense Webster, Inc. at 47.8% of the total. Reporting peaked in 2023 at $15,730 and has fallen 81.5% since, to $2,913 in 2025.

$62,326in general payments, 2019–2025

Across 211 payments — averaging $295.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$30K
  • Boston Scientific$11K
  • Pfizer$9K
  • Medical Device Business Services, Inc.$7K
  • Abbott$3K
  • Medtronic$3K
  • plus $885 from 17 others

What the payments were for

  • Consulting fees$31,47450%
  • Speaking & faculty fees$17,40028%
  • Travel & lodging$5,97110%
  • Food & beverage$7,44012%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,326 in reported general payments places this provider in the 85th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$326,235
Medicare patients
1,438
Services billed
4,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban731$891,911
MultaqDronedarone Hcl95$125,230
XareltoRivaroxaban66$79,536
EntrestoSacubitril/Valsartan47$58,764
Flecainide Acetate227$16,615
JardianceEmpagliflozin13$9,713
Amiodarone Hcl313$6,378
Metoprolol Succinate278$4,288
Nifedipine ErNifedipine121$3,348
Diltiazem 24hr Er (La)Diltiazem Hcl14$2,940
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$1,480
Pantoprazole Sodium77$762
Amlodipine Besylate114$734
Carvedilol86$705
Atorvastatin Calcium86$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,654$891,911731 claims
NovartisEntresto$24$58,76447 claims
Boehringer IngelheimJardiance$24$9,71313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →